Purpose: To review a single-center experience over a 27-year period of managing uterine carcinosarcoma (UCS), focusing on surgical practice, adjuvant therapy and clinical outcome. Material and Methods: This was a retrospective study of women with histologically proven UCS treated at the Department of Obstetrics and Gynecology, University of Tübingen, Germany, between 1983 and 2010. Inpatient and outpatient records were reviewed; follow-up and survival data were ascertained. Results: The study population comprised 18 patients with UCS. Primary surgical treatment consisted of total abdominal hysterectomy in 12 patients (67 %) and laparoscopic total hysterectomy in 4 patients (22 %). Bilateral salpingo-oophorectomy was performed in 94 % of patients (17/18). Lymph nodes were evaluated in 15 patients (83 %). Positive pelvic lymph nodes were present in 2 patients (11 %). A total of 17 patients (94 %) received adjuvant therapy. Disease recurred in 7 (39 %) patients of our study group, with no recurrence noted in the 4 patients who underwent laparoscopic surgical staging. Median disease-free survival (DFS) was 48.7 months (95 % CI: 0.0-157.3) and median overall survival (OS) was 49.9 months (95 % CI: 0.0-108.2). The 5-year survival rate was 40 %. Conclusion: UCS is a rare and aggressive uterine neoplasm with high recurrence rates and metastatic potential. Surgical staging consisting of total hysterectomy with bilateral salpingo-oophorectomy and systematic lymphadenectomy is the most important treatment for patients with UCS. Adjuvant radiation therapy appears to decrease pelvic recurrence, but there is a high incidence of distant recurrence, indicating the need for additional systemic treatment.
Purpose: To review a single-center experience over a 27-year period of managing uterine carcinosarcoma (UCS), focusing on surgical practice, adjuvant therapy and clinical outcome. Material and Methods: This was a retrospective study of women with histologically proven UCS treated at the Department of Obstetrics and Gynecology, University of Tübingen, Germany, between 1983 and 2010. Inpatient and outpatient records were reviewed; follow-up and survival data were ascertained. Results: The study population comprised 18 patients with UCS. Primary surgical treatment consisted of total abdominal hysterectomy in 12 patients (67 %) and laparoscopic total hysterectomy in 4 patients (22 %). Bilateral salpingo-oophorectomy was performed in 94 % of patients (17/18). Lymph nodes were evaluated in 15 patients (83 %). Positive pelvic lymph nodes were present in 2 patients (11 %). A total of 17 patients (94 %) received adjuvant therapy. Disease recurred in 7 (39 %) patients of our study group, with no recurrence noted in the 4 patients who underwent laparoscopic surgical staging. Median disease-free survival (DFS) was 48.7 months (95 % CI: 0.0-157.3) and median overall survival (OS) was 49.9 months (95 % CI: 0.0-108.2). The 5-year survival rate was 40 %. Conclusion: UCS is a rare and aggressive uterine neoplasm with high recurrence rates and metastatic potential. Surgical staging consisting of total hysterectomy with bilateral salpingo-oophorectomy and systematic lymphadenectomy is the most important treatment for patients with UCS. Adjuvant radiation therapy appears to decrease pelvic recurrence, but there is a high incidence of distant recurrence, indicating the need for additional systemic treatment.
Authors: Bhavana Pothuri; Lois Ramondetta; Patricia Eifel; Michael T Deavers; Andrew Wilton; Kaled Alektiar; Richard Barakat; Robert A Soslow Journal: Gynecol Oncol Date: 2006-07-25 Impact factor: 5.482
Authors: R Rothmund; A Hartkopf; C Joachim; C B Walter; M Wallwiener; B Kraemer; S Y Brucker; A Staebler; F A Taran Journal: Arch Gynecol Obstet Date: 2014-07-01 Impact factor: 2.344
Authors: H J Mackay; R J Buckanovich; H Hirte; R Correa; P Hoskins; J Biagi; L P Martin; G F Fleming; R Morgan; L Wang; R Polintan; A M Oza Journal: Gynecol Oncol Date: 2011-12-02 Impact factor: 5.482
Authors: Halla S Nimeiri; Amit M Oza; Robert J Morgan; Dezheng Huo; Laurie Elit; James A Knost; James L Wade; Edem Agamah; Everett E Vokes; Gini F Fleming Journal: Gynecol Oncol Date: 2010-02-01 Impact factor: 5.482
Authors: Warner K Huh; Michael W Sill; Kathleen M Darcy; Kevin M Elias; James S Hoffman; John F Boggess; Ronald D Alvarez; Harry J Long; David M O'Malley; Michael J Birrer Journal: Gynecol Oncol Date: 2010-02-26 Impact factor: 5.482
Authors: Carol Aghajanian; Michael W Sill; Angeles Alvarez Secord; Matthew A Powell; Margaret Steinhoff Journal: Gynecol Oncol Date: 2012-05-24 Impact factor: 5.482
Authors: D Denschlag; F C Thiel; S Ackermann; P Harter; I Juhasz-Boess; P Mallmann; H-G Strauss; U Ulrich; L-C Horn; D Schmidt; D Vordermark; T Vogl; P Reichardt; P Gaß; M Gebhardt; M W Beckmann Journal: Geburtshilfe Frauenheilkd Date: 2015-10 Impact factor: 2.915
Authors: I Kloos; S Delaloge; P Pautier; M Di Palma; A Goupil; P Duvillard; P E Cailleux; C Lhomme Journal: Int J Gynecol Cancer Date: 2002 Sep-Oct Impact factor: 3.437
Authors: Giacomo Corrado; Francesca Ciccarone; Francesco Cosentino; Francesco Legge; Andrea Rosati; Martina Arcieri; Luigi Carlo Turco; Camilla Certelli; Alex Federico; Enrico Vizza; Francesco Fanfani; Giovanni Scambia; Gabriella Ferrandina Journal: J Cancer Res Clin Oncol Date: 2020-09-03 Impact factor: 4.553